Matches in Wikidata for { <http://www.wikidata.org/entity/Q105088572> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q105088572 description "clinical trial" @default.
- Q105088572 description "ensayo clínico" @default.
- Q105088572 description "ensayu clínicu" @default.
- Q105088572 description "klinisch onderzoek" @default.
- Q105088572 description "клінічне випробування" @default.
- Q105088572 description "临床试验" @default.
- Q105088572 name "Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb" @default.
- Q105088572 name "Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb" @default.
- Q105088572 type Item @default.
- Q105088572 label "Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb" @default.
- Q105088572 label "Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb" @default.
- Q105088572 prefLabel "Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb" @default.
- Q105088572 prefLabel "Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb" @default.
- Q105088572 P1050 Q105088572-F9470759-4C0F-4AA4-A6ED-3BFB19D107CE @default.
- Q105088572 P1132 Q105088572-DCE72BBB-74D3-4726-9BC9-7B288E3E31D8 @default.
- Q105088572 P1476 Q105088572-A2E57060-E6EA-42DB-A37C-DFF95E2D9171 @default.
- Q105088572 P17 Q105088572-BED16B02-D230-42F9-A20E-05037C0F3B91 @default.
- Q105088572 P2899 Q105088572-A60FE8AA-9237-4968-B8A0-AE130F818A9F @default.
- Q105088572 P3098 Q105088572-A3BA76A1-9D15-4884-82A8-4611C3481E47 @default.
- Q105088572 P31 Q105088572-0B0A99B9-867C-4815-9221-3065DA8E2E57 @default.
- Q105088572 P580 Q105088572-767A561F-47BF-433D-B3DE-EF24AA0A5E81 @default.
- Q105088572 P582 Q105088572-1B004B6D-0F97-418E-8C17-DDA09FE201BC @default.
- Q105088572 P6099 Q105088572-FE530F60-66AA-4740-BDF8-77276FDCE1B4 @default.
- Q105088572 P8005 Q105088572-F4EFBDD0-FE49-4329-B586-A87BAB9F2CCF @default.
- Q105088572 P8363 Q105088572-4DF87FED-14F7-41D4-8814-7D5287491C8F @default.
- Q105088572 P859 Q105088572-D41B6065-65CF-495C-A6AB-E2475742212B @default.
- Q105088572 P921 Q105088572-64D83506-38EF-4881-9EE4-8FF191C361F3 @default.
- Q105088572 P921 Q105088572-F9EAB007-484F-4285-A49A-58345F206FDD @default.
- Q105088572 P1050 Q467635 @default.
- Q105088572 P1132 "+150" @default.
- Q105088572 P1476 "AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF PF-06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY" @default.
- Q105088572 P17 Q30 @default.
- Q105088572 P2899 "+16" @default.
- Q105088572 P3098 "NCT04649359" @default.
- Q105088572 P31 Q30612 @default.
- Q105088572 P580 "2021-01-14T00:00:00Z" @default.
- Q105088572 P582 "2022-06-25T00:00:00Z" @default.
- Q105088572 P6099 Q42824440 @default.
- Q105088572 P8005 Q76649614 @default.
- Q105088572 P8363 Q78089383 @default.
- Q105088572 P859 Q206921 @default.
- Q105088572 P921 Q263609 @default.
- Q105088572 P921 Q64064942 @default.